Creso Pharma (ASX: CPH) and Virbac have launched a natural complementary feed for companion animals containing a standardised amount of hemp extract with cannabidiol (CBD), the non-psychoactive substance of the hemp plant.
Unveiled in Switzerland, the new product anibidiol, supports a companion animals’ immune system and contributes to balanced behaviour.
Creso Pharma says anibidiol is the first Swiss Agroscope conformed complementary feed for.
The company said this proprietary combination of CBD, the fatty acids Omega 3, Omega 6 and Omega 9, terpenes, flavonoids, and other active herbal ingredients have a complex interaction which enhances their overall health-promoting effect.
The company said the anibidiol product range directly addresses the need for natural, non – pharmaceutical therapeutic approaches which are well tolerated by animals.
It says the CBD contained in anibidiol does not cause GI and dependency side effects and has a very good safety and tolerability profile.
Creso Pharma CEO and Co-Founder Dr Miri Halperin Wernli said that in order to guarantee professional advice anibidiol is marketed in Switzerland exclusively by Virbac and only through veterinary practices.
Virbac is a global pharmaceutical animal health company with a presence in over 100 countries and more than 4,800 employees and sales subsidiaries in 31 countries. With a turnover of €872 million in 2016, Virbac ranks today as the 7th largest pharmaceutical veterinary company worldwide.
“We are very excited to launch anibidiol in Switzerland and thrilled to be working in partnership with Virbac, such a well-established global company in the animal health field,” Dr Wernli said.
“This is the first introduction of our hemp-based complementary feed products for companion animals in the veterinary market.
“It is a particularly significant launch for us as it is Creso’s first product launch in Europe and we intend to follow it with many more.”